Find your path to Carlos
334 people in our graph share verified history with Carlos — schools, employers, funds. One of them is your warm intro.
Dan LynchunlockedCarlos: together at Blueprint Medicines (2018–2024)
Carlos: together at University of Wisconsin-Madison
Carlos: together at The George Washington University
Carlos: together at Blueprint Medicines
About
Dr. Garcia-Echeverria has held senior scientific and executive roles at biopharmaceutical companies including EQRx, Sanofi, and Novartis, with a focus on drug discovery and early-stage clinical development. He currently works as a scientific and strategic advisor to biopharma companies and venture capital firms, advising on drug discovery programs, development strategies, and partnerships. He holds a PhD in organic chemistry from the University of Barcelona and has authored 190 peer-reviewed publications and secured 45 granted patents.
Invests in
Biotech
Experience
- Cancer Research HorizonsMember of the Therapeutic Innovation Boardcurrent2024 — present
- GARDOM CONSULTING S.L.Foundercurrent2024 — present
- Blueprint MedicinesMember of the Scientific Advisory Board2018 — 2024Cambridge, Massachusetts, United States
- EQRxChief of Rx Creation2021 — 2023London, England, United Kingdom
- SanofiChief Operating Officer of Research / Global Head of Research Platforms2020 — 2021Paris, Ile-de-France, France
- SanofiVP, Global Head of Research Platforms2016 — 2020Paris Area, France
- SanofiVP, Global Head of Small Molecule Drug Discovery2014 — 2016Paris Area, France
- SanofiDeputy Global Head of Oncology Drug Discovery and Preclinical Research2010 — 2014Vitry-sur-Seine (France)
- NovartisExecutive Director - Oncology Drug Discovery Head2005 — 2010Basel Area, Switzerland
- NovartisPrograme Team Head - Novartis Leading Scientist1993 — 2005Basel Area, Switzerland
Skills & more
Drug Discovery51Drug Development21Biotechnology23Medicinal Chemistry32Biochemistry6Biophysical ChemistryBiopharmaceuticals6Pharmacology18Cancer Research4Technology Transfer8Outsourcing1Clinical Development9
+9 more
Life SciencesDrug DesignOncologyCRO ManagementDrug discoveryPharmaceutical IndustryManagementCROINDFrom Carlos's professional profile.
Colleagues at Ysios Capital
Almudena Méndez
Associate at Ysios Capital
Antoni Ribas
Venture Partner at Ysios Capital
Arturo Urrios
Partner at Ysios Capital
Carlos Paya
Venture Partner at Ysios Capital
Catalina Cuchy
Executive Assistant at Ysios Capital
Cristina Garmendia
General Partner at Ysios Capital
David L. Lacey
Venture Partner at Ysios Capital
Guillem Laporta
Partner at Ysios Capital
Frequently asked questions
- Who is Carlos Garcia-Echeverria?
- Dr. Garcia-Echeverria has held senior scientific and executive roles at biopharmaceutical companies including EQRx, Sanofi, and Novartis, with a focus on drug discovery and early-stage clinical development. He currently works as a scientific and strategic advisor to biopharma companies and venture capital firms, advising on drug discovery programs, development strategies, and partnerships. He holds a PhD in organic chemistry from the University of Barcelona and has authored 190 peer-reviewed publications and secured 45 granted patents.
- Where does Carlos Garcia-Echeverria work?
- Carlos Garcia-Echeverria is Scientific and Strategic Advisor at Ysios Capital.
- What does Carlos Garcia-Echeverria invest in?
- Carlos Garcia-Echeverria invests in Biotech.
- Where did Carlos Garcia-Echeverria go to school?
- Carlos Garcia-Echeverria studied at Universitat de Barcelona (Doctor of Philosophy (PhD), Organic Chemistry); University of Wisconsin-Madison (Medicinal and Pharmaceutical Chemistry); The George Washington University (Master Certificate in Project Management).
Same school
Also attended Universitat de Barcelona176
Santiago ReganDirector of Business Development at Redpoint VenturesAndrea AmadorCompliance Manager at Inveready Technology Investment GroupNelson CardonaController at Inveready Technology Investment GroupJosep Maria EcharriManaging Partner & CEO at Inveready Technology Investment GroupMar FernándezMarketing & Communications Manager at Inveready Technology Investment GroupAntonio HerceDirector at Inveready Technology Investment Group
+ 170 more
Also attended University of Wisconsin-Madison628
Zhenyu TangInvestment Director at Intel CapitalDougAdvisor at Clear VenturesDan RuchPartner at Rho VenturesJoe HayesInvestor at LightbankGeorge RobertsInvestor at OpenView Venture PartnersBret L. BostwickMD, FAAP, FACMG, Venture Advisor at Breyer Capital
+ 622 more
Also attended The George Washington University383
RustyAdvisor at Clear VenturesDonna HoyleVice President & Controller at RevolutionMathew KayeAccounting Manager at RevolutionMeghan FahyDirector of Marketing at GreycroftMaurice RussoInvestor at Lerer HippeauZach CollinsPartner at Mission Biocapital
+ 377 more
Shared employers
Also worked at Cancer Research Horizons2
Also worked at Blueprint Medicines11
Dan LynchInvestor at GV (Google Ventures)Rami RahalPartner at MPM BioImpactDeborah PalestrantPartner, Executive Chair, 4:59 Initiative at 5AM VenturesAlexis BorisyOperating Chairman at Curie.BioChristoph LengauerCSO at Curie.BioAndy GarnerSenior Vice President at Curie.Bio
+ 5 more
Also worked at Sanofi249
Steve LiapisManaging Director at Northpond VenturesWalter OlesiakOperating Partner at Remiges Ventures, Inc.Christine AylwardFounder & Managing Partner at Magnetic VenturesAlan WaltsVenture Partner at Advent Life SciencesSun AltbachSenior Scientific Advisor at BOLD LongevityMatt VineSenior Associate at RRE Ventures
)
+ 243 more
Also worked at Novartis332
Rebecca JamesInvestor at Index VenturesScott BillerInvestor at GV (Google Ventures)Freya Svedberg-KeatingInvestor at MedicxiAndrea AmadorCompliance Manager at Inveready Technology Investment GroupAbbie CelnikerInvestor at Third Rock VenturesJesper GromadaInvestor at Third Rock Ventures
+ 326 more